Ovarian carcinoma: An overview of current status
Abstract
Keywords
Full Text:
PDFReferences
Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, et al. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 2007; 23(5–6): 367–376. doi: 10.1155/2007/ 474320.
Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26(6): 995–1005. doi: 10.1200/JCO.2006.07.9970.
Fathalla MF. Incessant ovulation – A factor in ovarian neoplasia? Lancet 1971; 298(7716): 163. doi: 10.1016/ S0140-6736(71)92335-X.
Tortolero-Luna G, Mitchell MF. The epidemiology of ovarian cancer. J Cell Biochem 1995; 59(Suppl 23): 200–207. doi: 10.1002/jcb.240590927.
Rao BR, Slotman BJ. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 1991; 12(1): 14–26. doi: 10.1210/edrv-12-1-14.
Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Carcinoma Inst 1998; 90(23): 1774– 1786. doi: 10.1093/jnci/90.23.1774.
Kuroda H, Mandai M, Konishi I, Tsuruta Y, Kusakari T, et al. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2001; 91(3): 309–315. doi: 10.1002/ 1097-0215(200002)9999:9999<::AID-IJC1¬0-60>3.0.CO;2-0.
Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer – A short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007; 269(1–2): 61–64. doi: 10.1016/ j.mce.2006.11.014.
Bonello N, McKie K, Jasper M, Andrew L, Ross N, et al. Inhibition of nitric oxide: Effects on interleukin-1 beta-enhanced ovulation rate, steroid hormones, and ovarian leukocyte distribution at ovulation in the rat. Biol Reprod 1996; 54(2): 436–445. doi: 10.1095/biolreprod54.2.436.
The oncology committee of the International Federation of Gynecology and Obstetrics. FIGO news: Changes to the 1985 FIGO report on the result of treatment in gy-naecological cancer. Int J Gynecol Obstet 1987; 25(1): 87–88. doi: 10.1016/0020-7292(87)90233-5.
National Ovarian Cancer Coalition [Internet]. Dallas, Texas. [cited 2015 Oct 17]. Available from: http://www. ovarian.org/types_and_stages.php.
McCluggage WG. Morphological subtypes of ovarian carcinoma: A review with emphasis on new developments and pathogenesis. Pathol2011; 43(5): 420–432. doi: 10.1097/PAT.0b013e328348a6e7.
Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma — Evidence supporting the clonal relationship of the two le-sions. J Pathol 2012; 226(3): 421–426. doi: 10.1002/ path.3023.
Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer 1993; 71(Suppl S2): 566– 572. doi: 10.1002/cncr.2820710212.
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011. CA: Cancer J Clin 2011; 61(4): 212–236. doi: 10.3322/caac.20121.
Chester C, Dorigo O, Berek JS, Kohrt H. Immunotherapeutic approaches to ovarian cancer treatment. J Immunother Cancer 2015; 3: 7. doi: 10.1186/s40425-015- 0051-7.
Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory. Am J Surg Pathol 2010; 34(3): 433–443. doi: 10.1097/PAS. 0b013e3181cf3d79.
Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. BioMed Res Int 2014; 2014: 934261. doi: 10.1155/2014/934261.
Iyer VR, Lee SI. MRI, CT, and PET/CT for ovarian cancer detection and adnexal lesion characterization. AJR Am J Roentgenol 2010; 194(2): 311–321. doi: 10.2214/ AJR.09.3522.
Burges A, Schmalfeldt B. Ovarian cancer: Diagnosis and treatment. Dtsch Arztebl Int 2011; 108(38): 635–641. doi: 10.3238/arztebl.2011.0635.
Ezzati M,Abdullah A,Shariftabrizi A, Hou J, Kopf M, et al. Recent advancements in prognostic factors of epithelial ovarian carcinoma. Int Sch Res Notices 2014; 2014: 953509. doi: 10.1155/2014/953509.
Raja FA, Chopra N, Ledermann JA. Optimal first-line treatment in ovarian cancer. Ann Oncol 2012; 23 (Suppl 10): x118–x127. doi: 10.1093/annonc/mds315.
Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 2012; 109(10): 3921–3926.doi: 10.1073/pnas.1117135109.
Garcia A, Singh H. Bevacizumab and ovarian cancer. Ther Adv Med Oncol 2013; 5(2): 133–141. doi: 10.1177/ 1758834012467661.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. [cited 2015 Nov 25]. Available from: http://globocan.iarc.fr.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. [cited 2015 Nov 22]. Available from: http://glo-bocan.iarc.fr.
Angelina Jolie's effect: Risk factors for ovarian cancer! [Internet]. India: Zee Media Corporation Ltd. [cited 2015 Oct 17]. Available from: http://zeenews.india.com/news/ health/diseases-conditions/angelina-jolies-effect-risk-factors-for-ovarian-carcinoma_1566989.html.
SEER Cancer Statistics Review 1975–2013. [Internet]. USA: National Cancer Institute; 2010. [cited 2015 Nov 20]. Available from: http://seer.cancer.gov/archive/ csr/1975_2013/results_merged/topic_survival.pdf.
Ovarian cancer statistics. [Internet]. Washington, DC: Ovarian Cancer National Alliance; 2015. [cited 2015 Nov 20]. Available from: http://www.ovariancancer.org/wp- content/uploads/2015/06/Statistics-2015_final.pdf.
Husmann G, Kaatsch P, Katalinic A, Bertz J, Haberland J, et al. (German) [Krebs in Deutschland: 2005/2006; Häufigkeiten und trends; Eine gemeinsame Veröffen-tlichung des Robert Koch-Instituts und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.]. Berlin: Robert Koch-Institut; 2010. Available from: http: //www.rki.de/DE/Content/Gesundheitsmonitoring/Gesun-dheitsberichterstattung/GBEDownloadsB/KID2010.pdf?_blob=publicationFile.
Shih IM, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164(5): 1511–1518. doi: 10.1016/S0002-9440(10)63708-X.
McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008; 61(2): 152–163. doi: 10.1136/jcp.2007.049478.
Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008; 27(2): 161–174. doi: 10.1097/PGP.0b013e31815ea812.
Three year report of population based cancer registries 2012-2014: Incidence, distribution, trends in incidence rates and projections of burden of cancer. [Internet]. Bengaluru, India: National Centre for Disease Informatics and Research, National Cancer Registry Programme, and Indian Council Medical Research. [cited 2016 May 2016]. Available from: http://www.ncrpindia.org/ALL_NCRP_ REPORTS/PBCR_REPORT_2012_2014/ALL_CONTENT/Printed_Version.htm.
Lagos VI, Perez MA, Ricker CN, Blazer KR, Santiago NM, et al. Social-cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psychooncology 2008; 17(8): 774–782. doi: 10.1002/pon.1358.
Ricciardelli C, Oehler MK. Diverse molecular pathways in ovarian cancer and their clinical significance. Maturitas 2009; 62(3): 270–275. doi: 10.1016/j.maturitas.2009. 01.001.
Schuijer M, Berns EMJJ. TP53 and ovarian cancer. Hum Mutat 2003; 21(3): 285–291. doi: 10.1002/humu.10181.
Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, et al. Pooled analysis of 3 European case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 1991; 49(1): 50–56. doi: 10.1002/ijc. 2910490110.
Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991; 49(1): 57–60. doi: 10.1002/ijc. 2910490111.
Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, et al. Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use. Int J Cancer 1991; 49(1): 61–65. doi: 10.1002/ijc. 2910490112.
Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Lancet 1994; 343(8899): 692–695. doi: 10.1016/S0140-6736(94)91578-4.
Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Peragallo Urrutia R, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Re-port/Technology Assessment No. 212. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-2007-10066-I.) AHRQ Publication No. 13-EHC033- EF. [Internet]. Rockville, MD: Agency for Healthcare Research and Quality. [cited 2015 Oct 20]. Available from: https://effectivehealthcare.ahrq.gov/ehc/products/416/1530/cancer-ovarian-contraceptives-executive-130611.pdf.
Havrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, et al. Oral contraceptive pills as primary prevention for ovarian cancer: A systematic review and meta-analysis. Obstet Gynecol 2013; 122(1): 139–147. doi: 10.1097/AOG.0b013e318291c235.
Tomao F, Russo GL, Spinelli GP, Stati V, Prete AA, et al. Fertility drugs, reproductive strategies and ovarian cancer risk J Ovarian Res 2014; 7: 51. doi: 10.1186/1757- 2215-7-51.
Risch HA, Marrett LD, Howe GR. Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 1994; 140(7): 585–597.
Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer — Shifting the paradigm. Hum Pathol 2011; 42(7): 918–931. doi: 10.1016/j.humpath.2011.03.003.
Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJJ, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001; 195(4): 451– 456. doi: 10.1002/path.1000.
Piek JMJ, Kenemans, P, Verheijen RHM. Intraperitoneal serous adenocarcinoma: A critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004; 191(3): 718–732. doi: 10.1016/j.ajog.2004.02.067.
Maeda D, Takazawa Y, Ota S, Takeuchi Y, Seta A, et al. Bilateral microscopic adenocarcinoma of the fallopian tubes detected by an endometrial cytologic smear. Int J Gynecol Pathol 2010; 29(3): 273–277. doi: 10.1097/PGP. 0b013e3181c30301.
Przybycin CG, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (non-uterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010; 34(10): 1407–1416. doi: 10.1097/PAS.0b013e3181ef7b16.
Royal College of Pathologists. Datasets for the histopathological reporting of neoplasms of the ovaries and fallopian tubes and primary carcinomas of the peritoneum. London: Royal College of Pathologists; 2008.
Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganised orphan papillae. Int J Gynecol Pathol 2010; 29(6): 507– 512. doi: 10.1097/PGP.0b013e3181e31f74.
Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopath-ologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16(5): 267–282. doi: 10.1097/PAP.0b013e3181b4fffa.
Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 2004; 23(1): 41–44. doi: 10.1097/01.pgp.0000101080.35393.16.
Köbel M, Kalloger SE, Santos JL, Huntsman DG, Blake Gilks C, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: Insights and implications. Gynecol Oncol 2010; 116(1): 50–56. doi: 10.1016/ j.ygyno.2009.09.029.
Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol 2006; 103(3): 1122– 1129. doi: 10.1016/j.ygyno.2006.08.012.
Benito V, Lubrano A, Arencibia O, Medina N, Eva EA, et al. Serous and mucinous borderline ovarian tumors: Are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 2010; 153(2): 188–192. doi: 10.1016/j.ejogrb.2010.07.024.
Singer G, Oldt R III, Cohen Y, Wang BG, Sidransky D, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95(6): 484–486. doi: 10.1093/jnci/ 95.6.484.
Tan DSP, Kaye S. Ovarian clear cell adenocarcinoma: A continuing enigma. J Clin Pathol 2007; 60(4): 355–360. doi:10.1136/jcp.2006.040030.
Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363(16): 1532–1543. doi: 10.1056/NEJMoa1008433.
Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol2000; 24(11): 1465–1479. doi: 10.1097/ 00000478-200011000-00002.
Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, et al. Malignancy in endometriosis: Frequency and com-parison of ovarian and extraovarian types. Int J Gynecol Pathol 2001; 20(2): 133–139. doi: 10.1097/00004347- 200104000-00004.
Obata K, Morland SJ, Watson RH, Hitchcock A, Chen-evix-Trench G, et al. Frequent PTEN/MMAC1 mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58(10): 2095–2097.
Catasús L, Bussaglia E, Rodríguez I, Gallardo A, Pons C, et al. Molecular genetic alterations in endometrioid car-cinomas of the ovary: Similar frequency of beta-cat¬enin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 2004; 35(11): 1360–1368. doi: 10. 1016/j.humpath.2004.07.019.
Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, et al. Advances in the recognition of tubal intra-epithelial carcinoma: Applications to cancer screening and the pathogenesis of ovarian carcinoma. Adv Anat Pathol 2006; 13(1): 1–7. doi: 10.1097/01.pap.000020182 6.46978.e5.
Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007; 211(1): 26–35. doi: 10.1002/path.2091.
Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol 2007; 31(2): 161–169. doi: 10.1097/01.pas. 0000213335.40358.47.
Herrington CS, McCluggage WG. The emerging role of the distal fallopian tube and p53 in pelvic serous carcinogenesis. J Pathol 2010; 220(1): 5–6. doi: 10.1002/ path.2630.
Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM. Muta-tions of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 2004; 64(19): 6915–6918. doi: 10.1158/0008-5472.CAN-04-2067.
Sieben NLG, Macropoulos P, Roemen GMJM, Kolkman-Uljee SM, Jan Fleuren G, et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 2004; 202(3): 336– 340. doi: 10.1002/path.1521.
Singer G, Stöhr R, Cope L, Dehari R, Hartmann A, et al. Patterns of p53 mutations separate ovarian serous border-line tumors and low- and high-grade carcinomas and pro-vide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation. Am J Surg Pathol 2005; 29(2): 218–224. doi: 10.1097/01.pas.0000146025.91953.8d.
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28(4): 496–504. doi: 10.1097/00000478-200404000-00009.
Sala E. Ovarian cancer: imaging in treatment selection and planning with FIGO update. Cancer Imaging 2014; 14(Suppl 1): 018. doi: 10.1186/1470-7330-14-S1-O18.
Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. Anticancer Res 2006; 26(1): 647–653.
Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351(24): 2519–2529. doi: 10.1056/NEJMra041842.
Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010; 116(3): 378– 383. doi: 10.1016/j.ygyno.2009.10.087.
Skates, SJ. Ovarian cancer screening: Development of the Risk of Ovarian Cancer Algorithm(ROCA) and ROCA screening trials. Int J Gynecol Cancer 2012; 22(Suppl 1): S24–S26. doi: 10.1097/IGC.0b013e318256488a.
FIGO ovarian cancer staging. [Internet]. [cited 2015 Aug 15]. Available from: https://www.sgo.org/wp-content/ up-loads/2012/09/FIGO-Ovarian-Cancer-Staging_1.10.14.pdf.
Fehrmann RSN, Li XY, van der Zee AGJ, de Jong S, te Meerman GJ, et al. Profiling studies in ovarian cancer: A review. Oncologist 2007; 12(8): 960–966. doi: 10.1634/theoncologist.12-8-960.
Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25(5): 517–525. doi: 10.1200/JCO. 2006.06.3743.
Ahmed FY,Wiltshaw E, A’Hern RP, Nicol B, Shepherd J, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996; 14(11): 2968–2975.
Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357(9251): 176–182. doi: 10. 1016/S0140-6736(00)03590-X.
Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95; 155-163. doi: 10.1056/NEJM199002083220602.
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009; 374(9698): 1371–1382. doi: 10.1016/ S0140-6736(09)61338-6.
Parker WH, Broder MS, Chang E, Feskanich DS, Far-quhar C, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet Gynecol 2009; 113(5): 1027–1037. doi: 10.1097/AOG.0b013e3181a11c64.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, et al. ICON and AGO collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVA R-2.2 trial. Lancet 2003; 361(9375): 2099–2106. doi: 10.1016/ S0140-6736(03)13718-X.
Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: A meta-analysis. Cancer Treat Rev 2012; 38(6): 613–617. doi: 10.1016/j.ctrv.2011.10.008.
Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, et al. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91(6): 747-754. doi:10.1002/bjs.4473.
Kuhn E, Tisato V, Rimondi E, Secchiero P. Current pre-clinical models of ovarian cancer. J Carcinog Mutagen 2015; 6(2): 220. doi: 10.4172/2157-2518.1000220.
De Felice F, Marchetti C, Palaia I, Musio D, Muzii L, et al. Immunotherapy of ovarian cancer: The role of checkpoint inhibitors. J Immunol Res 2015; 2015: 1-7. doi: 10.1155/2015/191832.
McCabe N, Turner NC, Lord CJ, Kluzek K, Białkowska A, Swift S, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66(16): 8109–8115. doi: 10.1158/0008-5472. CAN-06-0140.
Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor α, in epithelial ovarian carcinoma: A Phase I study. Clin Cancer Res 2010; 16(21): 5288–5295. doi: 10.1158/1078-0432.CCR-10-0700.
Seoung J, Park Y, Rhim C, Kim S. Current possible drug therapies for ovarian cancer. J Cancer Ther 2014; 5: 1203–1214. doi: 10.4236/jct.2014.513122.
Lipkowitz S, Kohn EC. To treat or not to treat: The use of hormone replacement therapy in patients with ovarian cancer. J Clin Oncol 2015; 33(35): 4127–4128. doi: 10.1200/JCO.2015.63.6670.
Chen RF, Li J, Zhu TT, Yu HL, Lu X. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): Single institution experience. J Ovarian Res 2016; 9: 16. doi: 10.1186/s13048-016-0226-y.
Ditto A, Martinelli F, Lorusso D, Haeusler E, Carcangiu M, et al. Fertility sparing surgery in early stage epithelial
ovarian cancer. J Gynecol Oncol 2014; 25(4): 320–327. doi: 10.3802/jgo.2014.25.4.320.
Seong SJ, Kim DH, Kim MK, Song T.Controversies in borderline ovarian tumors. J Gynecol Oncol 2015; 26(4): 343–349. doi: 10.3802/jgo.2015.26.4.343.
Holderfield M, Deuker MM, McCormick F,McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14(7): 455–467. doi: 10.1038/nrc3760.
Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016; 3: 3. doi: 10.1186/s40661-016-0024-7.
Vasconcelos I, Gaspar O. Meta-analysis of the PARP inhibitor olaparib reveals therapeutic efficacy in ovarian cancer independent of BRCA1/2 mutation status. Adv Mod Oncol Res 2016; 2(1): 91–96; http://dx.doi.org/ 10.18282/amor.v2.i2.54.
Panguluri SK, Yeakel C, Kakar SS. PTTG: An important target gene for ovarian cancer therapy. J Ovarian Res 2008; 1: 6. doi: 10.1186/1757-2215-1-6.
Hardwick N, Chung V, Cristea M, Ellenhorn JD, Diamond DJ. Overcoming immunosuppression to enhance a p53MVA vaccine. Oncoimmunology 2014; 3(10): 958949. doi: 10.4161/21624011.2014.958949.
Azvolinsky A. Anti-PD-1 antibody nivolumab shows activity in ovarian cancer. [Internet]. US: UBM Medica, LLC; 2015. [cited 2015 Aug 15]. Available from: http:// www.cancernetwork.com/gynecologic-cancers/anti-pd-1-antibody-nivolumab-shows-activity-ovarian-cancer.
DOI: http://dx.doi.org/10.30564/amor.v2i5.80
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Yogita Lugani, Smita Asthana, Satyanarayana Labani

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.